COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE AND BACTERIAL INFECTION
Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a subject in need thereof. Some aspects may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. The intracellular damage may be a result of a disease such as Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis or tuberculosis. In some aspects, a method of treating tuberculosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating atherosclerosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating peritonitis is disclosed, comprising administering PIF to a subject in need thereof.
1 . A method of treating intracellular damage comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, compositions thereof, mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof.
2 . The method of claim 1 further comprising administering a potassium channel inhibitor.
3 . The method of claim 2 , wherein the potassium channel inhibitor is a Kv1.3 inhibitor.
4 . The method of claim 3 , wherein the potassium channel inhibitor is IFNγ.
5 . The method of claim 1 , wherein the intracellular damage is the result of a disease selected from Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis or tuberculosis.
6 . The method of claim 1 , wherein the treating further comprises increasing cytokine secretion in response to the intracellular damage.
7 . A method of treating intracellular infection comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, compositions thereof, mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof.
8 . The method of claim 7 further comprising administering a potassium channel inhibitor.
9 . The method of claim 8 , wherein the potassium channel inhibitor is a Kv1.3 inhibitor.
10 . The method of claim 8 , wherein the potassium channel inhibitor is IFNγ.
11 . The method of claim 7 , wherein the intracellular infection is selected from Listeria monocytogenes, Mycobacterium tuberculosis, Heliobacter pylori, Borrelia burgdorferi sensu stricto, Borelia afzelii , and Borrelia garinii.
12 . A method of treating peritonitis comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, compositions thereof, mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof.
13 . The method of claim 12 further comprising administering a potassium channel inhibitor.
14 . The method of claim 13 , wherein the potassium channel inhibitor is a Kv1.3 inhibitor.
15 . The method of claim 13 , wherein the potassium channel inhibitor is IFNγ.
16 . A method of reducing lipids comprising administering to a subject in need thereof a therapeutically effective amount of a PIF peptide selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, compositions thereof, mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof.
17 . The method of claim 16 further comprising administering a potassium channel inhibitor.
18 . The method of claim 17 , wherein the potassium channel inhibitor is a Kv1.3 inhibitor or IFNγ.
19 . The method of claim 16 , wherein the treating comprises reducing plaque, reducing monocyte proteins, reducing lipids, reducing cytokines and combinations thereof.
20 . The method of claim 19 , wherein the reducing is completed in an aortic arch, an aortic root and combinations thereof.